Geneticist Francis Collins calls for further study of Aplidin to combat Covid

The principle in Aplidin, Pharmamar’s cancer drug, shows potent antiviral activity against Covid, according to Collins.

Geneticist Francis Collins calls for further study of Aplidin to combat Covid

“The prince of Plitidepsin has also successfully completed a phase I / II clinical study for the treatment of COVID-19 conducted by the pharmaceutical company PharmaMar and is moving towards a phase II / III study of COVID-19.” It is part of the report “Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A” that was published a few weeks ago in Science.

A statement corroborated by the eminent geneticist Francis Collins on Twitter. “In preclinical research, the investigational cancer drug plitidepsin shows potent antiviral activity against Covid, suggesting the need for further evaluation of this drug for this use.”

The drug Aplidin – trade name of the active substance plitidepsin- sounded from the beginning as the great hope against Covid-19, a disease that, a year later, is characterized by not having any specific treatment with overwhelming efficacy.

With the publication in the prestigious magazine Science the active principle is defined as around 100 times more potent than the only drug specifically approved against Covid-19, remdesivir.

This news is added to other positive ones about the drug. This same month, the expert Luis Enjuanes of the CSIC endorsed the effectiveness of Aplidín in an intervention on the autonomous television of Castilla y León, Enjuanes has endorsed the data obtained: “I am sure because I have verified it”.

The phase II results presented by the pharmaceutical company are promising: the drug is safe and reduces viral load in all types of patientssaid the expert, adding: “In the laboratory we have verified that aplidine has good results.”

“And not only have there been checks in Spain,” also in Korea and New York, where they have scored much better than us for this drug, “added Enjuanes, anticipating the work published in Science.

This news is added to other positive ones about the drug. This same month, the expert Luis Enjuanes of the CSIC endorsed the effectiveness of Aplidín in an intervention on the autonomous television of Castilla y León, Enjuanes has endorsed the data obtained: “I am sure because I have verified it”.

The phase II results presented by the pharmaceutical company are promising: the drug is safe and reduces viral load in all types of patientssaid the expert, adding: “In the laboratory we have verified that aplidine has good results.”

“And not only have there been checks in Spain,” also in Korea and New York, where they have scored much better than us for this drug, “added Enjuanes, anticipating the work published in Science.